Skip to main content
. 2024 Nov 25;14(11):e084846. doi: 10.1136/bmjopen-2024-084846

Figure 1. Patient recruitment scheme. Randomised participants will be assigned to either the canagliflozin (100 mg once daily) treatment group or the control group for a period of 6 months. Following this initial phase, participants in both groups continue to receive canagliflozin. Patients in the canagliflozin group continue the medication for an additional 6 months, while those in the control arm are switched to canagliflozin for another 12 months as a delayed-start canagliflozin group. T2D, type 2 diabetes.

Figure 1